<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nanobiotix Sa — News on 6ix</title>
<link>https://6ix.com/company/nanobiotix-sa-1</link>
<description>Latest news and press releases for Nanobiotix Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 21 May 2026 13:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nanobiotix-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d53525beedb30cb6f6eb7e.webp</url>
<title>Nanobiotix Sa</title>
<link>https://6ix.com/company/nanobiotix-sa-1</link>
</image>
<item>
<title>Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-1</guid>
<pubDate>Thu, 21 May 2026 13:30:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time). Trading of the ordinary shares of</description>
</item>
<item>
<title>Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris</guid>
<pubDate>Thu, 21 May 2026 06:30:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of the market</description>
</item>
<item>
<title>Nanobiotix Announces Launch of Global Follow-On Offering</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-launch-of-global-follow-on-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-launch-of-global-follow-on-offering-1</guid>
<pubDate>Wed, 20 May 2026 22:19:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the launch, subject to market and other conditions, of an approximately €75 million global follow-on offering (representing approximately $87 million) consisting of (i) a public offering o</description>
</item>
<item>
<title>Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study-1</guid>
<pubDate>Mon, 04 May 2026 21:29:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study. This protocol amendment, submitted by NANORAY-312 global sponsor Johnson & Johnson, eliminates the previously plan</description>
</item>
<item>
<title>Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after-pre-treatment-with-nanoprimer-technology-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after-pre-treatment-with-nanoprimer-technology-1</guid>
<pubDate>Mon, 20 Apr 2026 06:30:00 GMT</pubDate>
<description>Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearancePre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (“LNP-DNA”) designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nano</description>
</item>
<item>
<title>Voting Rights and Shares Capital of the Company</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/voting-rights-and-shares-capital-of-the-company-23</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/voting-rights-and-shares-capital-of-the-company-23</guid>
<pubDate>Tue, 07 Apr 2026 20:15:00 GMT</pubDate>
<description>In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, April 07, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2</description>
</item>
<item>
<title>NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-provides-business-update-and-reports-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-provides-business-update-and-reports-full-year-2025-financial-results-1</guid>
<pubDate>Tue, 31 Mar 2026 20:15:00 GMT</pubDate>
<description>Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the</description>
</item>
<item>
<title>NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-presentation-of-first-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-presentation-of-first-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer-1</guid>
<pubDate>Mon, 30 Mar 2026 06:30:00 GMT</pubDate>
<description>Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical</description>
</item>
<item>
<title>NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-announce-fourth-quarter-and-full-year-2025-operational-and-financial-update-on-march-31st-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-announce-fourth-quarter-and-full-year-2025-operational-and-financial-update-on-march-31st-2026-1</guid>
<pubDate>Thu, 26 Mar 2026 20:15:00 GMT</pubDate>
<description>Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CESTPARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended Dece</description>
</item>
<item>
<title>NANOBIOTIX Statement Regarding Recent Media Speculation</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-statement-regarding-recent-media-speculation-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-statement-regarding-recent-media-speculation-1</guid>
<pubDate>Wed, 25 Mar 2026 14:11:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over. Nanobiotix states that, to the best of its knowledge, there is no such intent</description>
</item>
<item>
<title>NANOBIOTIX to Participate in Investor Conferences in March</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-participate-in-investor-conferences-in-march-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-participate-in-investor-conferences-in-march-1</guid>
<pubDate>Wed, 25 Feb 2026 21:15:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:1</description>
</item>
<item>
<title>NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-join-cac-mid-60-and-sbf-120-indices-on-euronext-paris</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-join-cac-mid-60-and-sbf-120-indices-on-euronext-paris</guid>
<pubDate>Mon, 15 Dec 2025 07:30:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes wi</description>
</item>
<item>
<title>Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-provides-third-quarter-2025-operational-and-financial-update-along-with-2026-clinical-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-provides-third-quarter-2025-operational-and-financial-update-along-with-2026-clinical-outlook</guid>
<pubDate>Mon, 24 Nov 2025 21:15:00 GMT</pubDate>
<description>Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Cu</description>
</item>
<item>
<title>NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-curadigm-nanoprimer-platform-advancements-with-updated-plans-for-internal-pipeline-development-and-external-collaborations</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-curadigm-nanoprimer-platform-advancements-with-updated-plans-for-internal-pipeline-development-and-external-collaborations</guid>
<pubDate>Thu, 13 Nov 2025 21:15:00 GMT</pubDate>
<description>Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborationsNew in vivo pre-clinical data evaluating the Nanoprimer in combination with therapeutic vaccines were presented at the 2025 Partnership Opportunities in Drug Delivery conference (PODD) that will serve as the foundation for an initial internal proprietary pipeline of</description>
</item>
<item>
<title>NANOBIOTIX to Participate in Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-participate-in-jefferies-london-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-participate-in-jefferies-london-healthcare-conference</guid>
<pubDate>Tue, 11 Nov 2025 21:15:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference: Jefferies London Healthcare ConferenceDate: Monday, November 17, 2025Time: 3pm GMT / 10am ET / 4pm CETLoca</description>
</item>
<item>
<title>NANOBIOTIX to Participate in Investor Conferences the Week of November 10th</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-participate-in-investor-conferences-the-week-of-november-10th</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-to-participate-in-investor-conferences-the-week-of-november-10th</guid>
<pubDate>Mon, 03 Nov 2025 21:15:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: UBS Global Healthcare ConferenceDate: Monday, November 10, 2025Time: 5pm ET / 11pm CETLocation: Palm Beach Gar</description>
</item>
<item>
<title>NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-strategic-royalty-monetization-agreement-with-healthcare-royalty-for-up-to-dollar71-million-and-extends-cash-runway-toward-long-term-growth</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-strategic-royalty-monetization-agreement-with-healthcare-royalty-for-up-to-dollar71-million-and-extends-cash-runway-toward-long-term-growth</guid>
<pubDate>Fri, 31 Oct 2025 07:00:00 GMT</pubDate>
<description>$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial foundation toward self-sustainability and the advancement of next wave nanotherapeutic platforms for long-term growthHealthCare Royalty (HCRx) will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3) payable to Nanobiotix under its global licensing agreem</description>
</item>
<item>
<title>NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-updates-to-jnj-1900-nbtxr3-clinical-program-following-transfer-of-ongoing-phase-3-head-and-neck-cancer-trial-sponsorship-and-operational-control</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-updates-to-jnj-1900-nbtxr3-clinical-program-following-transfer-of-ongoing-phase-3-head-and-neck-cancer-trial-sponsorship-and-operational-control</guid>
<pubDate>Fri, 24 Oct 2025 06:00:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr</description>
</item>
<item>
<title>NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-first-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-for-patients-with-esophageal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-announces-first-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-for-patients-with-esophageal-cancer</guid>
<pubDate>Wed, 01 Oct 2025 20:15:00 GMT</pubDate>
<description>Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responsesRecruitment of 17 additional patients is ongoing as planned Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NANOB</description>
</item>
<item>
<title>NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results</title>
<link>https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-provides-business-update-and-reports-half-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/nanobiotix-sa-1/news/nanobiotix-provides-business-update-and-reports-half-year-2025-financial-results-1</guid>
<pubDate>Tue, 30 Sep 2025 20:15:00 GMT</pubDate>
<description>PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding c</description>
</item>
</channel>
</rss>